214 related articles for article (PubMed ID: 37051238)
1. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.
Sun L; Liu Z; Wu Z; Ning K; Hu J; Chen Z; Wu Z; Yin X
Front Immunol; 2023; 14():1113455. PubMed ID: 37051238
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of Golgi apparatus-related genes indicates prognosis and immune infiltration in osteosarcoma.
Zhang J; Liu J; Ding R; Miao X; Deng J; Zhao X; Wu T; Cheng X
Aging (Albany NY); 2024 Mar; 16(6):5249-5263. PubMed ID: 38460960
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtype identification and prognosis stratification based on golgi apparatus-related genes in head and neck squamous cell carcinoma.
Zhang A; He X; Zhang C; Tang X
BMC Med Genomics; 2024 Feb; 17(1):53. PubMed ID: 38365684
[TBL] [Abstract][Full Text] [Related]
4. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of Golgi apparatus-related signature for predicting prognosis and immunotherapy response in breast cancer.
Chen X; Tang P; Kong Y; Chen D; Tang K
J Cancer Res Clin Oncol; 2024 Feb; 150(2):61. PubMed ID: 38300336
[TBL] [Abstract][Full Text] [Related]
6. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.
Sun L; Wu Z; Dong C; Yu S; Huang H; Chen Z; Wu Z; Yin X
BMC Med Genomics; 2023 Jun; 16(1):130. PubMed ID: 37316840
[TBL] [Abstract][Full Text] [Related]
7. Establishment of Golgi apparatus-related genes signature to predict the prognosis and immunotherapy response in gastric cancer patients.
Liu R; Chu W; Liu X; Hong J; Wang H
Medicine (Baltimore); 2024 Mar; 103(11):e37439. PubMed ID: 38489711
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
10. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
11. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
12. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
13. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
[TBL] [Abstract][Full Text] [Related]
14. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
15. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
16. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
17. Signature construction and molecular subtype identification based on liver-specific genes for prediction of prognosis, immune activity, and anti-cancer drug sensitivity in hepatocellular carcinoma.
Zhang X; Xiao Z; Zhang X; Li N; Sun T; Zhang J; Kang C; Fan S; Dai L; Liu X
Cancer Cell Int; 2024 Feb; 24(1):78. PubMed ID: 38374122
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
[TBL] [Abstract][Full Text] [Related]
19. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
20. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Yang Y; Xiao W; Liu R; Gao L; Chen J; Kan H
J Immunol Res; 2022; 2022():4983532. PubMed ID: 36405011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
